Table 2.
Baseline characteristics and comparison of the 2 groups.
| Chemical prophylaxis | Mechanical prophylaxis | p value | |||||
|---|---|---|---|---|---|---|---|
| N | N | ||||||
| Age (mean/SD) | 329 | 57.45 | 16.67 | 419 | 58.99 | 16.37 | 0.206 |
| Gender (n/%) | 329 | 419 | |||||
| Male | 182 | 55.32% | 238 | 56.80% | |||
| Female | 147 | 44.68% | 181 | 43.20% | 0.685 | ||
| Race (n/%) | 327 | 416 | |||||
| American Indian | 2 | 0.61% | 1 | 0.24% | |||
| Asian/Pacific Islander | 4 | 1.22% | 8 | 1.92% | |||
| Black | 132 | 40.37% | 130 | 31.25% | |||
| Latin/Hispanic | 44 | 13.46% | 52 | 12.50% | |||
| White | 144 | 44.04% | 223 | 53.61% | |||
| Other | 1 | 0.31% | 2 | 0.48% | 0.103 | ||
| APACHE II point sum (mean/SD) | 288 | 19.8 | 7.78 | 369 | 20.53 | 7.24 | 0.215 |
| Active cancer | 329 | 33 | 10% | 419 | 53 | 12.6% | 0.265 |
| History of DVT/PE | 329 | 18 | 5.5% | 419 | 11 | 2.6% | 0.045 |
| HTN (n/%) | 329 | 208 | 63.2% | 419 | 239 | 57.0% | 0.087 |
| CAD (n/%) | 329 | 52 | 15.8% | 419 | 63 | 15.0% | 0.772 |
| CHF (n/%) | 329 | 51 | 15.5% | 419 | 44 | 10.5% | 0.041 |
| CVA (n/%) | 329 | 38 | 11.6% | 419 | 54 | 12.9% | 0.580 |
| COPD (n/%) | 329 | 63 | 19.1% | 419 | 43 | 10.3% | 0.001 |
| DM (n/%) | 329 | 112 | 34.0% | 419 | 112 | 26.7% | 0.030 |